Furthermore, it is recommended that IgG, IgA, or FLC associated MGRS should be treated with as per the treatment algorithm for MM, and IgM associated MGRS should follow the treatment algorithm for WM2,3. The gene discussed is CD79A; the disease is Miyoshi myopathy.